Cannabinoid composition and application of the same in preparing medicine for treating neurodegenerative diseases including parkinson's disease and alzheimer's disease
US11497719B1 · kind B1 · utility
Inventors
Key dates
| Filing date | Jan 27, 2022 |
| Grant date | Nov 15, 2022 |
| Priority date | — |
| Expiry date | Jan 27, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/28
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are a cannabinoid composition and an application of the same in preparing a medicine for treating neurodegenerative diseases, so as to solve the drawbacks of conventional medicines such as serious side effects and degraded therapeutic effect after long-term administration. The cannabinoid composition includes: cannabidiol and cannabigerol, a mass ratio of the cannabidiol to the cannabigerol ranging from 1:1 to 1:10, or from 1:0.3 to 1:0.5, or from 1:0.5 to 1:0.7, or from 1:07 to 1:1. The present disclosure adopts the experimental method of inducing differentiation of fibroblasts to dopaminergic neurons, wherein by observing the cell morphology, quantity, and relative expression level of DA-related factor of the differentiation-induced and cultured fibroblasts, and screening various common cannabinoids and different combinations thereof based on their impacts on inducing differentiation of the fibroblasts into dopaminergic neurons, it was found that the CBD+CBG combination offered an optimal effect in improving viability and dopamine-secreting capability of the dopaminergic neuronal cells; besides, the CBD+CBG combination is free of the addictive substance THC, which thus …
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.